A therapeutic exploratory (phase II, NCT00628290), double-blinded, monocenter, randomized, parallel-group, controlled clinical trial of CBD vs. amisulpride efficacy in patients (n = 39, 18–59 y) with diagnosis of schizophrenia or schizophreniform psychosis. All participants were assessed for psychotic symptoms, and measurements of serum prolactin and body weight were taken. Safety measures included repeated electrocardiograms as well as routine blood parameters. Here, PRL is linked to schizophrenia.